TP53 and neoplasm: CB11 expression was more frequent in the TP53(−) than in the TP53(+) carcinomas (30 vs 18%, P=0.04), as well as in FIGO IV tumours than in other clinical stages (43% expressors in stage IV, 19% in stage IIIC, 20% in IIIA and B, 29% in IIB and C, P=0.032).